Introduction
Brand name: Astconazole‑100
Manufacturer: Astemax Biotech
Composition: Posaconazole 100 mg gastro‑resistant tablet
Astconazole‑100 is a systemic triazole antifungal tablet containing posaconazole 100 mg in a gastro‑resistant (enteric‑coated) form. It is indicated for the prophylaxis and treatment of invasive fungal infections in immunocompromised patients, such as those with haematological malignancies, stem‑cell transplant recipients, or severe neutropenia.
Key features
Mechanism: Posaconazole inhibits lanosterol 14α‑demethylase (CYP51), blocking ergosterol biosynthesis in fungal cell membranes, thereby exerting broad‑spectrum activity against Aspergillus, Candida, and other moulds and yeasts.
Gastro‑resistant formulation improves gastric stability and is generally preferred over oral suspension for higher and more consistent plasma exposure when given with or without food.
Main indications
Prophylaxis: Prevention of invasive fungal infections in high‑risk haematology/transplant patients.
Salvage therapy: Treatment of invasive aspergillosis and other refractory mycoses when first‑line antifungals are not tolerated or effective.
Astconazole‑100 can be positioned as a WHO‑GMP‑oriented, high‑strength, gastro‑resistant posaconazole tablet for haematologists, oncologists, and critical‑care prescribers managing invasive fungal infections and prophylaxis in immunocompromised patients.
